Abstract:Pancreatic cancer is a highly lethal disease with a 5-year survival rate less than 5% due to the lack of an early diagnosis method and effective therapy. To provide a novel early diagnostic method and targeted therapy for pancreatic cancer, a multifunctional nanoimmunoliposome with high loading of ultrasmall superparamagnetic iron oxides (USPIOs) and doxorubicin (DOX) was prepared by transient binding and reverse-phase evaporation method, and was conjugated with anti-mesothelin monoclonal antibody by post-insertion method to target anti-mesothelin-overexpressed pancreatic cancer cells. The in vitro and in vivo properties of this anti-mesothelin antibody-conjugated PEGlyated liposomal DOX and USPIOs (M-PLDU; and PEGlyated nanoimmunoliposome without antibody conjugation [PLDU]) were evaluated both in human pancreatic cancer cell line Panc-1 cell and in a pancreatic cancer xenograft animal model. Results showed that M-PLDUs were spherical and uniform with a diameter about similar to 180 nm, with a zeta potential of about -28 similar to-30 mV, and had good efficacy encapsulating DOX and USPIOs. The in vitro study demonstrated that M-PLDUs possessed good magnetic resonance imaging (MRI) capability with a transverse relaxivity (r(2)) of about 58.5 mM(-1) . s(-1). Confocal microscopy showed more efficient uptake of M-PLDU in Panc-1 cells by antibody-mediated targeting. Methyl thiazolyl tetrazolium assay results showed significant inhibitory effect of M-PLDU against Panc-1 cells (half-maximal inhibitory concentration, 1.95 mu M). The in vivo imaging study showed that the tumor signal intensity (SI) dropped significantly about 4 hours after intravenous injection of M-PLDU. The decrease in tumor SI induced by M-PLDUs (Delta SI = 145.98 +/- 20.45) or PLDUs (Delta SI = 75.69 +/- 14.53) was much more significant than that by free USPIOs (Delta SI = 42.78 +/- 22.12; P < 0.01). The in vivo antitumor study demonstrated that compared with FD (free DOX) and PLDU, M-PLDU possessed higher inhibitory effect on tumor growth and the tissue distribution assay further proved that M-PLDUs could selectively accumulate in the tumor xenograft. These results indicated that M-PLDU not only well retained the inherent MRI capability of USPIOs, but significantly improved the targeting distribution of USPIOs and therapeutic agents in pancreatic tumor tissues. They may serve as a promising theranostic nanomedicine not only for early detection but also for MRI-monitored targeting therapy of human pancreatic cancer.

Development of Peptide Conjugated Superparamagnetic Iron Oxide (SPIO) Nanoparticles for Targeted MR Imaging and Therapy of Pancreatic Cancer

Targeting Pancreatic Cancer Cells with Peptide-Functionalized Polymeric Magnetic Nanoparticles

PCN-Fe(III)-PTX Nanoparticles for MRI Guided High Efficiency Chemo-Photodynamic Therapy in Pancreatic Cancer Through Alleviating Tumor Hypoxia

Superparamagnetic Iron Oxide Nanoparticles for MR Imaging of Pancreatic Cancer: Potential for Early Diagnosis Through Targeted Strategies

Molecular Imaging of Pancreatic Cancer in an Animal Model Using Targeted Multifunctional Nanoparticles.

Dual-targeted and MRI-guided Photothermal Therapyviairon-Based Nanoparticles-Incorporated Neutrophils

Theranostic Nanoparticles With Controlled Release Of Gemcitabine For Targeted Therapy And Mri Of Pancreatic Cancer

Development of Receptor Targeted Magnetic Iron Oxide Nanoparticles for Efficient Drug Delivery and Tumor Imaging.

Drug delivery particles for targeted imaging-guided photothermal/chemotherapy synergy cancer therapy

IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.

Functionalized Milk-Protein-coated Magnetic Nanoparticles for MRI-monitored Targeted Therapy of Pancreatic Cancer.

A MSLN-targeted Multifunctional Nanoimmunoliposome for MRI and Targeting Therapy in Pancreatic Cancer

MUC‐1 aptamer targeted superparamagnetic iron oxide nanoparticles for magnetic resonance imaging of pancreatic cancer in vivo and in vitro experiment

The effect of superparamagnetic iron oxide with iRGD peptide on the labeling of pancreatic cancer cells in vitro: a preliminary study

Crgd-Functionalized, DOX-conjugated, and 64Cu-Labeled Superparamagnetic Iron Oxide Nanoparticles for Targeted Anticancer Drug Delivery and PET/MR Imaging

Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-Guided Drug Delivery into Peritoneal Tumors Following Intraperitoneal Delivery

Advanced Iron Oxide Nanotheranostics for Multimodal and Precision Treatment of Pancreatic Ductal Adenocarcinoma

Survivin-Targeted Nanoparticles for Pancreatic Tumor Imaging in Mouse Model.

Doxorubicin-modified magnetic nanoparticles as a drug delivery system for magnetic resonance imaging-monitoring magnet-enhancing tumor chemotherapy

Multifunctional Ph-Sensitive Superparamagnetic Iron-Oxide Nanocomposites for Targeted Drug Delivery and Mr Imaging

Sialic Acid-Engineered Mesoporous Polydopamine Nanoparticles Loaded with SPIO and Fe3+ As a Novel Theranostic Agent for T1/T2 Dual-Mode MRI-guided Combined Chemo-Photothermal Treatment of Hepatic Cancer